Skip Navigation

Adalvo Leads the Way with First European Approval for Apremilast

21 February 2024

Adalvo is pleased to announce that Apremilast 10mg, 20mg, and 30mg film-coated tablets has received its first approval in Europe. Having gained approval in December 2023, this positions Adalvo as the first company to reach this milestone.

Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in the treatment of Psoriatic Arthritis, Psoriasis and Behçet’s disease.

With global sales of $4 billion in 2022 and a steady 3Y CAGR of 9%, according to IQVIA, Adalvo's Apremilast offers a promising value proposition, backed by a positive cost of goods.

Having obtained Marketing Authorizations (MAs) for Apremilast in numerous European countries, including Bulgaria, Czech Republic, Hungary, Iceland, Italy, Poland, Romania, Slovakia, and Spain, Adalvo is strategically seeking a single partner to optimize market penetration effectively.

Partner up now!  

At Adalvo, we believe in the power of collaboration to drive success. As the pioneer in bringing Apremilast to European markets, we are committed to optimising market penetration effectively. If you're seeking a strategic partner to propel your business forward and maximize the potential of Apremilast, reach out to us now by clicking on one of our BD members below. – Europe - South Europe - West Europe North Europe, CEE & APAC – North America & Canada - LATAM (exc. Brazil) - Brazil & MENA – Brands & Specialty Products - Head of Global BD&L

Click on your preferred Business Partner and get in touch today!